Lindbrook Capital, LLC Alkermes Plc. Transaction History
Lindbrook Capital, LLC
- $1.18 Billion
- Q3 2024
A detailed history of Lindbrook Capital, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 389 shares of ALKS stock, worth $12,276. This represents 0.0% of its overall portfolio holdings.
Number of Shares
389
Previous 336
15.77%
Holding current value
$12,276
Previous $8,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ALKS
# of Institutions
357Shares Held
180MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$919 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$599 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$410 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$399 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$290 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.18B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...